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1 |  INTRODUCTION
Doyne honeycomb retinal dystrophy (DHRD) and malattia 
leventinese (ML) refer to autosomal dominant progressive 
retinal diseases characterized by the accumulation of macular 
and peripapillary yellow- white deposits (drusen) beneath the 
retinal pigment epithelium in Bruch's membrane (Doyne, 
1899; Evans et al., 1997; Piguet et al., 1995). With age, dru-
sen increase in size and number, often to form a characteris-
tic honeycomb- like pattern (Doyne, 1899; Evans et al., 1997; 
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Abstract
Background: Doyne honeycomb retinal dystrophy (DHRD)/malattia leventinese 
(ML) is an autosomal dominant, progressive retinal disorder characterized by massive 
central retinal drusen often partly coalescent forming a characteristic honeycomb- like 
pattern. Debut of vision loss often occurs in early to mid- adulthood, and the degree 
varies. A single variant in EFEMP1: c.1033C>T (R345W) has been identified as the 
cause in all cases.
Methods: Following DNA isolation, exome sequencing was performed in seven genes 
associated with flecked retina. Direct sequencing was used for variant verification.
Results: We report the first Scandinavian case of molecular genetically verified 
DHRD/ML: a 57- year- old woman debuting with vision loss and metamorphopsia. On 
both eyes, ophthalmological findings included massive hard drusen in the macular re-
gion and nasal to the optic disc as well as macular hyperpigmentation. Secondary cho-
roidal neovascularizations were identified on both eyes, and anti- vascular endothelial 
growth factor was administered, without effect.
Conclusion: Molecular genetic investigation revealed heterozygosity for the known 
pathogenic missense variant in EFEMP1: c.1033C>T (R345W) previously reported 
in relation to DHRD/ML. Family history revealed no other cases of similar visual 
impairment suggesting a de novo mutation. Furthermore, there was no correlation 
between the unique DHRD/ML haplotypes reported in the literature and our patient.
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Piguet et al., 1995; Scarpatetti et al., 1978). Massive drusen, 
geographic retinal atrophy, and macular hyperpigmentation 
eventually cause visual symptoms such as decreased visual 
acuity, metamorphopsia, photophobia, and paracentral sco-
toma often debuting around age of 40– 50 years (Evans et al., 
1997; Heon et al., 1996; Scarpatetti et al., 1978). Complicating 
secondary choroidal neovascularizations (CNVs) and hemor-
rhage can lead to rapid progression (Pager et al., 2001; Piguet 
et al., 1995; Sohn et al., 2011; Zech et al., 1999).
Complete penetrance in DHRD/ML and a great variabil-
ity in phenotype/severity have been described (Evans et al., 
1997; Marmorstein, 2004; Takeuchi et al., 2010).
DHRD was first reported by Doyne in 1899 (Doyne, 
1899), and ML was initially described in patients with fa-
milial drusen living in the Levantine Valley in Switzerland in 
1925 (Vogt, 1925). An autosomal dominant inheritance and 
the overlapping phenotype suggested that the two retinal dis-
eases represented the same disorder (Forni & Babel, 1962; 
Waardenburg, 1948). However, subsequent funduscopic de-
scriptions revealed differences in composition and distribu-
tion of retinal drusen, for example, with drusen appearing in a 
more radial pattern in ML, which was not a prominent feature 
in DHRD (Evans et al., 1997; Piguet et al., 1995). Despite 
these small discrepancies possibly explained by different ge-
netic backgrounds and/or environmental influences, a single 
pathogenic variant in EFEMP1 (MIM 601548): c.1033C>T 
(R345W) was found by Stone et al. in 1999, to be the cause 
of both conditions (Stone et al., 1999). Consequently, in the 
following, they will be referred to as the same disease.
The EFEMP1 gene is localized on chromosome 2p16.1 
and encodes the epidermal growth factor- containing fibrillin- 
like extracellular matrix protein 1 (Efemp1, fibulin 3), the 
function of which remains to be fully elucidated. Protein mis-
folding and basal deposit formation in retinal pigment epi-
thelium containing Efemp1 have been observed in EFEMP1 
R345W affected and is believed to be responsible for drusen 
formation (Fu et al., 2007; Marmorstein et al., ,2002, 2007; 
Roybal et al., 2005). In 2005, Roybal et al. discovered that the 
R345W variant led to increased expression of vascular endo-
thelial growth factor (VEGF), known to play a pivotal role 
in the development of complicating CNVs also observed in 
DHRD/ML. Furthermore, dense confluent drusen formation 
can possibly induce hypoxia, which is known to stimulate 
VEGF expression in retinal pigment epithelium promoting 
CNV development (Mousa et al., 1999).
The disease- causing mechanism of the EFEMP1 R345W 
mutation is not thought to be caused by a loss- of- function 
effect based on the complete absence of histopathological 
features compatible with DHRD/ML in EFEMP1 knockout 
mouse (McLaughlin et al., 2007). In EFEMP1 knockout 
mouse, however, early aging and multiple hernias have been 
observed, suggesting connective tissue disorder (McLaughlin 
et al., 2007). This is in contrast to EFEMP1 knock- in mouse 
carrying the R345W mutation, where no other apparent 
extraretinal pathology has been described (Fu et al., 2007; 
Marmorstein et al., 2007). This is supported by current 
knowledge on DHRD/ML where disease is limited to the ret-
ina. In a few case reports regarding pronounced connective 
tissue disorder, biallelic variants in EFEMP1 with suspected 
loss of function have been described as the cause (Bizzari 
et al., 2020; Driver et al., 2020). In both these cases, several 
phenotypic similarities with Marfan syndrome exist; how-
ever, EFEMP1 is currently not associated with any connec-
tive tissue disorder.
In the 39 families (Switzerland, the United States, and 
Australia) studied by Stone et al. (1999), the absence of de 
novo mutations and areas with loss of heterozygosity (com-
plete sharing of alleles of four intragenic EFEMP1 poly-
morphisms) suggested a common ancestor in all affected 
individuals. Since 1999, a three- digit number of geneti-
cally verified DHRD/ML has been reported in populations 
around the world, most cases being in the United Kingdom, 
the United States, Australia, Switzerland, and neighboring 
countries (Cusumano et al., 2019; Gregory et al., 1996; Heon 
et al., 1996; Matsumoto & Traboulsi, 2001; Narendran et al., 
2005; Serra et al., 2017; Sohn et al., 2011).
2 |  MATERIALS AND METHODS
2.1 | Clinical report
We present the molecular genetic findings of a 57- year- old 
Scandinavian woman of non- consanguineous Danish 
Caucasian parents debuting with vision loss and distorted vi-
sion primarily on the left eye at age of 47 years. Corrected 
visual acuity was reduced by 0.8/0.5  cc, respectively. On 
the left eye, metamorphopsia was reported using an Amsler 
grid. Ophthalmological examination revealed radially ori-
ented massive hard drusen partly coalescent on both eyes in 
the macular region and nasal to the disc as well as macular 
hyperpigmentation (Figure 1). Optical coherence tomography 
(OCT) on both eyes show foveal drusen and retinal atrophy on 
the left eye (Figure 2). Fluorescein angiography (FLU- A) and 
indocyanine green angiography (ICG- A) showed no signs of 
secondary CNVs. The patient was clinically diagnosed with 
DHRD/ML and followed annually with stable conditions.
Ten years later, reduced visual acuity (0.2/0.63 cc) and in-
creased atrophy with subretinal fluid were observed. FLU- A/
ICG- A indicated secondary CNVs on both eyes, and anti- 
vascular endothelial growth factor (anti- VEGF) was admin-
istrated in three consecutive treatments on both eyes, without 
effect. A follow- up FLU- A indicated, however, that the con-
dition was stable.
Family history revealed no other cases of reduced vision, 
and both the patient's parents are currently in their nineties. 
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The patient's 45- year- old younger sister underwent ophthal-
mological examination with normal findings and was thus 
not genotyped.
2.2 | Editorial policies and ethical 
considerations
Oral informed consent was obtained by the patient.
2.3 | Molecular evaluation and verification
Genomic DNA was obtained from blood leukocytes using 
standard procedures.
The sequencing analysis of seven genes associated with 
flecked retina was done by Amplexa genetics (Amplexa 
FleckRet7 Panel). A heterozygous mutation in EFEMP1 
(NM_001039348.3) c.1033C>T (R345W) was detected 
(Figure 3). No pathogenic variants were found in the rest 
of the sequenced genes. The detected mutation was ver-
ified by direct sequencing analysis of exon 10 of the 
EFEMP1 gene using the following primers: forward primer 
5′- TGCTCTCACACCTCCTTCCT- 3′ and reverse primer, 
5′- CACATGGCATTTGAGACTGG- 3′. The PCR amplifi-
cation was performed according to the following protocol: 
95°C for 2 min, followed by 30 cycles of 95°C for 15 s, 55°C 
for 30 s, 72°C for 30 s, and a final step of extension for 5 min 
at 72°C. Employed microsatellite markers included D2S378, 
F I G U R E  1  Fundus photography show 
massive, partly coalescent drusen in the 
macular area and nasal to the optic disc on 
both eyes. OD = right eye. OS = left eye
F I G U R E  2  Optical coherence 
tomography (OCT). OCT on both eyes show 
foveal drusen and retinal atrophy on the left 
eye. Arrowheads indicate the location of 
fovea. OD = right eye. OS = left eye
F I G U R E  3  Partial sequence electropherograms of exon 10 of 
EFEMP1 from our index patient and a control individual (wild type)
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D2S2352, and intragenic SNPs rs1346786, rs3791676, and 
rs1430197 (primers are available upon request) (Fu et al., 
2007; Stone et al., 1999). For sequencing and genotyping, 
samples from patient and controls were amplified by PCR 
and loaded on an ABI 3100 Genetic Analyzer System follow-
ing manufacturer's instructions. Fragment analysis was done 
using GeneMarker software 2.6.4 (SoftGenetics, LLC).
3 |  RESULTS
A known pathogenic variant NM_001039348 (EFEMP1): 
c.1033C>T (R345W) previously seen in relation to DHRD/
ML was identified in a heterozygote state in the index. No 
other causative variants were identified.
Haplotype analysis indicated a different haplotype com-
pared with the original study by Stone et al. (1999) (Table 1), 
suggesting that the mutation arose independently, although 
predictive testing in the family was not performed and paren-
tal data therefore remain unknown.
4 |  DISCUSSION
To the best of our knowledge, this is the first case of mo-
lecular genetically verified DHRD/ML in Scandinavia. 
Heterozygosity for the known pathogenic EFEMP1 variant 
R345W was shown to be the cause of visual impairment 
and DHRD/ML in this 57- year- old Caucasian Scandinavian 
woman. In our case, no family history of DHRD/ML was 
reported. We then speculated that DHRD/ML in our index 
therefore had to be explained either by a great variability in 
disease phenotype with a mildly affected and undiagnosed 
parent, different paternal origin, or a R345W de novo muta-
tion in our index. Since parental gene testing was not possi-
ble, a haplotype analysis was conducted in our index patient.
As previously mentioned, Stone et al. (1999) found ev-
idence of a common ancestor in all affected individuals. 
However, in 2007, Fu et al. reported a consanguineous Indian 
family with DHRD/ML where the R345W mutation segre-
gated with a different disease haplotype indicating that the 
mutation arose independently. Another unique haplotype was 
later in 2010 reported in a Japanese DHRD family (Takeuchi 
et al., 2010). In order to investigate a possible common an-
cestor of the mutation in our index patient, haplotype analy-
sis was performed, revealing a haplotype different from the 
Swiss R345W haplotype (Stone et al., 1999), thus indicating 
a de novo mutation with the proviso of absence of confirma-
tory data from the patient's parents.
DHRD/ML has been of special interest to researchers 
due to several similarities with age- related macular de-
generation (AMD), a leading cause of blindness in devel-
oped countries (Edwards et al., 1998; Wong et al., 2014). 
Retinal drusen is a hallmark in both DHRD/ML and AMD, 
although differences in extracellular matrix proteins have 
been reported (Sohn et al., 2015). To date, no mutation in 
EFEMP1 has been reported in AMD patients (Stone et al., 
1999).
No general recommendations regarding neither surgical 
nor medical treatment in DHRD/ML exist. Current research 
is primarily based on interventional case reports where minor 
beneficial effects of treatment with argon laser (Lenassi et al., 
2013) and subthreshold nanolaser (Cusumano et al., 2019) 
have been proposed. Based on the experience in treating neo-
vascular AMD (Lin & Rosenfeld, 2007), administration of 
anti- VEGF (bevacizumab) has been tried in DHRD/ML when 
complicated by CNV development, suggesting some benefi-
cial effect (Sohn et al., 2011). In this case, three consecutive 
treatments with anti- VEGF (Eylea) were administrated in 
both eyes; however, no increase in visual acuity was found, 
and no change in the retinal condition was registered. The 
need for additional clinical trials with long- term follow- up 
is therefore greatly needed in order to establish a potential 
effect of the previously mentioned and other treatments in 
DHRD/ML. This, however, is made difficult by the low num-
ber of affected individuals.
5 |  CONCLUSION
To the best of our knowledge, this case represents the 
first molecular genetically verified case of DHRD/ML in 
Scandinavia. Stone et al. (1999) found evidence of a common 
ancestor in all cases in the original study; however, haplotype 
comparison suggested a de novo mutation in our index, al-
though parental data remain unknown.
On both eyes, our index developed complicating CNVs, 
and treatment with anti- VEGF was administered, without a 
beneficial effect.
T A B L E  1  Haplotype data for two microsatellite markers flanking 






D2S2352a 321 319/321 315/321
R345W M/+ M/+ +/+
RS1346786 T/C T/C C/C
RS3791676 C/C C/T T/T
RS1430197 A/G A/G G/G
D25378a 368/381 370 370/380
The index patient exhibits a different disease haplotype from the previously 
described Swiss R345W haplotype. + = wild type; M = p.R345W mutation.
aMicrosatellite markers analysis are presented here by length of generated 
fragments (bp). 
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